靶向巨噬细胞YTHDC1/TIGAR/NF-κB轴缓解肺动脉高压
该研究探讨巨噬细胞YTHDC1在肺动脉高压(PH)炎症性血管重塑中的作用。在特发性或结缔组织病相关PAH患者中,YTHDC1和TIGAR在肺及循环巨噬细胞中表达升高且与疾病严重程度相关。髓系特异性敲除Ythdc1或Tigar可保护小鼠抵抗缺氧及SU5416/缺氧诱导的PH,药理抑制YTHDC1(YL-5092)或干扰TIGAR-TAK1相互作用(5Z-7-oxozeaenol)可减轻血管炎症并缓解PH进展。
要点
- 巨噬细胞YTHDC1/TIGAR/NF-κB轴是PH炎症和血管重塑的关键决定因素。
- YTHDC1和TIGAR在PAH患者巨噬细胞中升高,与疾病严重程度相关。
- 药理抑制YTHDC1或TIGAR-TAK1相互作用可缓解多种啮齿类PH模型。
核心结论
- 巨噬细胞YTHDC1/TIGAR/NF-κB信号轴是PH炎症和血管重塑的关键决定因素,可作为潜在生物标志物和治疗靶点。
研究设计与样本
- 在人和啮齿类PH标本中评估YTHDC1和TIGAR表达谱。
- 利用髓系特异性敲除小鼠和药理抑制剂(YL-5092、5Z-7-oxozeaenol)在缺氧、SU5416/缺氧和野百合碱诱导的PH模型中评估机制和治疗作用。
主要发现
- 在特发性或结缔组织病相关PAH患者中,YTHDC1和TIGAR在肺及循环巨噬细胞中表达升高,与疾病严重程度相关。
- 小鼠模型中,髓系特异性敲除Ythdc1或Tigar对缺氧和SU5416/缺氧诱导的PH提供显著保护。
- 缺氧上调Ythdc1,直接结合并稳定Tigar mRNA;Tigar蛋白通过特定结构域(残基152-161)非酶促地与Tak1相互作用,激活NF-κB级联,增强促炎细胞因子释放并驱动肺动脉平滑肌细胞增殖。
- 药理抑制YTHDC1(YL-5092)或破坏TIGAR-TAK1相互作用(5Z-7-oxozeaenol)可有效减轻多种啮齿类模型中的血管炎症并缓解PH进展。
临床怎么用
- 巨噬细胞YTHDC1/TIGAR/NF-κB轴可能作为PAH的生物标志物。
- 靶向YTHDC1或TIGAR-TAK1相互作用是PH的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Immune dysregulation is a pivotal driver of pulmonary hypertension (PH) pathogenesis, yet therapeutic targeting of inflammation has yielded limited clinical success. Although cytosolic RNA-binding proteins are known to regulate immune responses in PH, the specific role of the nuclear m⁶A reader YTHDC1 remains undefined. OBJECTIVES: To elucidate the function of macrophage YTHDC1 in orchestrating inflammatory vascular remodeling during PH. METHODS: Expression profiles of YTHDC1 and TP53-induced glycolysis and apoptosis regulator (TIGAR) were evaluated in human and rodent PH specimens. The mechanistic and therapeutic roles of this axis were assessed using myeloid-specific knockout mice and pharmacological inhibitors (YL-5092, 5Z-7-oxozeaenol) across hypoxia-, SU5416/hypoxia-, and monocrotaline-induced PH models. MEASUREMENTS AND MAIN RESULTS: In patients with idiopathic or connective tissue disease-associated PAH, YTHDC1 and TIGAR expression levels were elevated in pulmonary and circulating macrophages, correlating with disease severity. In murine models, myeloid-specific deletion of Ythdc1 or Tigar conferred profound protection against hypoxia- and SU5416/hypoxia-induced PH. Mechanistically, hypoxia upregulated Ythdc1, which directly bound and stabilized Tigar mRNA. The subsequent accumulation of Tigar protein operated non-enzymatically via a specific domain (residues 152-161) to interact with Tak1, thereby activating the NF-κB cascade, augmenting pro-inflammatory cytokine release, and driving pulmonary artery smooth muscle cell proliferation. Pharmacological inhibition of YTHDC1 (YL-5092) or disruption of the TIGAR-TAK1 interaction (5Z-7-oxozeaenol) effectively attenuated vascular inflammation and mitigated PH progression in diverse rodent models. CONCLUSIONS: The macrophage YTHDC1/TIGAR/NF-κB signaling axis acts as a critical determinant of inflammation and vascular remodeling in PH, representing a potential biomarker and therapeutic target for this disease.
引用
- Wang J, Feng Y, Shen Y, et al. Therapeutic Targeting of the Macrophage YTHDC1/TIGAR/NF-κB Axis Mitigates Pulmonary Hypertension. Am J Respir Crit Care Med. 2026. PMID: 42934119. doi:10.1093/ajrccm/aamag496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。